Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
Proteo Biotech AG / Key word(s): Study/Research Update Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study) 50% of Patients are enrolled and the planned interim safety analysis is successfully completed Irvine, CA – Kiel, June 22, 2012 Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today: The planned interim safety analysis of the EMPIRE study has already been conducted. No safety concerns were raised by the Data Monitoring Committee and the continuation of the trial was recommended. The recruitment has been especially impressive – fifty percent of the patients have already been treated in the ongoing Phase 2 clinical trial in coronary bypass surgery. The EMPIRE study (Elafin Myocardial Protection from Ischaemia Reperfusion Injury) – a placebo-controlled, double-blinded, monocentric Phase 2 study with 80 patients – has been started in the third quarter of 2011. The study investigates the efficacy of the naturally occurring human protease inhibitor Elafin in preventing complications of coronary bypass surgery with focus on cardiac muscle injury. The study is funded by the Medical Research Council (MRC) and Chest Heart & Stroke Scotland (CHSS) with funding in excess of 500,000 GBP. "We are very excited with the enrollment progress made in the EMPIRE Phase 2 clinical trial", said Birge Bargmann, CEO of Proteo. "The cooperation with the study centre is going very well and we are confident that the anticipated schedule for the study will be kept." The study is being performed under the supervision of the cardiologist Dr. Peter Henriksen at NHS Lothian's Edinburgh Heart Centre in association with The University of Edinburgh, one of the leading European universities in the area of cardiovascular research and the Edinburgh Clinical Trials Unit. "It's very exciting to be in this position and to be at the point where something that I worked on ten years ago in the tissue culture labs is now being administered to patients" said Peter Henriksen
Further information on the clinical development program for Elafin
About Proteo
Forward-looking statements
Contact
Email: info@proteo.de End of Corporate News 22.06.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
175098 22.06.2012 |